Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John F Carlquist

Showing results (1-10 of 84) with videos related to

Pageof 9
Sort By:
Discovery Medicine|May 28, 2011
Pharmacogenetic mechanisms underlying unanticipated drug responsesJohn F Carlquist, Jeffrey L Anderson
Circulation|August 3, 2005
Cytokines, interleukin-18, and the genetic determinants of vascular inflammationJeffrey L Anderson, John F Carlquist
Circulation|December 7, 2011
Using pharmacogenetics in real time to guide warfarin initiation: a clinician updateJohn F Carlquist, Jeffrey L Anderson
Journal of the American College of Cardiology|June 12, 2003
Genetic polymorphisms of hepatic lipase and cholesteryl ester transfer protein, intermediate phenotypes, and coronary risk: do they add up yet?Jeffrey L Anderson, John F Carlquist
American Journal of Clinical Pathology|May 13, 2006
Risk factor analysis of plasma cytokines in patients with coronary artery disease by a multiplexed fluorescent immunoassayThomas B Martins, Jeffrey L Anderson, Joseph B Muhlestein, et al.
Expert Review of Molecular Diagnostics|September 26, 2007
Lipoprotein-associated phospholipase A2: a new biomarker for cardiovascular risk assessment and potential therapeutic targetJohn F Carlquist, Joseph B Muhlestein, Jeffrey L Anderson
Current Atherosclerosis Reports|February 5, 2008
Progress in unraveling the genetics of coronary artery disease and myocardial infarctionJeffrey L Anderson, John F Carlquist, Benjamin D Horne, et al.
Molecular Diagnosis & Therapy|November 4, 2011
Genotype-based dosing algorithms for warfarin therapy: data review and recommendationsEric G Johnson, Benjamin D Horne, John F Carlquist, et al.
Journal of Cardiovascular Pharmacology and Therapeutics|March 26, 2003
Cardiovascular pharmacogenomics: current status, future prospectsJeffrey L Anderson, John F Carlquist, Benjamin D Horne, et al.
American Heart Journal|October 31, 2007
Associations with myocardial infarction of six polymorphisms selected from a three-stage genome-wide association studyBenjamin D Horne, John F Carlquist, Joseph B Muhlestein, et al.
Pageof 9

Showing results (1-10 of 84) with videos related to

Sort By:
Pageof 9
Discovery Medicine|May 28, 2011
Pharmacogenetic mechanisms underlying unanticipated drug responsesJohn F Carlquist, Jeffrey L Anderson
Circulation|August 3, 2005
Cytokines, interleukin-18, and the genetic determinants of vascular inflammationJeffrey L Anderson, John F Carlquist
Circulation|December 7, 2011
Using pharmacogenetics in real time to guide warfarin initiation: a clinician updateJohn F Carlquist, Jeffrey L Anderson
Journal of the American College of Cardiology|June 12, 2003
Genetic polymorphisms of hepatic lipase and cholesteryl ester transfer protein, intermediate phenotypes, and coronary risk: do they add up yet?Jeffrey L Anderson, John F Carlquist
American Journal of Clinical Pathology|May 13, 2006
Risk factor analysis of plasma cytokines in patients with coronary artery disease by a multiplexed fluorescent immunoassayThomas B Martins, Jeffrey L Anderson, Joseph B Muhlestein, et al.
Expert Review of Molecular Diagnostics|September 26, 2007
Lipoprotein-associated phospholipase A2: a new biomarker for cardiovascular risk assessment and potential therapeutic targetJohn F Carlquist, Joseph B Muhlestein, Jeffrey L Anderson
Current Atherosclerosis Reports|February 5, 2008
Progress in unraveling the genetics of coronary artery disease and myocardial infarctionJeffrey L Anderson, John F Carlquist, Benjamin D Horne, et al.
Molecular Diagnosis & Therapy|November 4, 2011
Genotype-based dosing algorithms for warfarin therapy: data review and recommendationsEric G Johnson, Benjamin D Horne, John F Carlquist, et al.
Journal of Cardiovascular Pharmacology and Therapeutics|March 26, 2003
Cardiovascular pharmacogenomics: current status, future prospectsJeffrey L Anderson, John F Carlquist, Benjamin D Horne, et al.
American Heart Journal|October 31, 2007
Associations with myocardial infarction of six polymorphisms selected from a three-stage genome-wide association studyBenjamin D Horne, John F Carlquist, Joseph B Muhlestein, et al.
Pageof 9